On August 13, Karyopharm Therapeutics (NASDAQ:KPTI) held its second-quarter earnings call, and the story split cleanly in two. The company laid out a myelofibrosis combination therapy with data strong enough to earn an accelerated approval pathway from the FDA, alongside a cash position that funds operations only into September. A $15.8 million loan payment lands September 10, and management admitted that paying it without new financing could trip a liquidity covenant and trigger default. Investors are being asked to weigh a genuinely differentiated drug against a genuinely short clock.
Bull Case: A Novel Combination With Real Data Behind It
The bull case rests on selinexor paired with ruxolitinib, which Karyopharm plans to submit for FDA review this month under the Accelerated Approval Pathway for myelofibrosis. The Phase III SENTRY study found statistically significant, rapid, deep, and sustained spleen volume reductions, along with a preliminary overall survival signal and hints of disease modification. At week 24, the combination nearly doubled the spleen response rate versus ruxolitinib alone, with responses showing up as early as week 12 and holding through week 36 across patient subgroups. Even when ruxolitinib was dosed below 15 milligrams a day, the combination produced SVR35 rates as high as 50%, compared with zero for ruxolitinib alone, suggesting doctors could trim ruxolitinib without losing efficacy.
The overall survival hazard ratio at the time of the topline analysis was 0.43. If cleared, this would be the first approved combination therapy in frontline myelofibrosis, a disease affecting roughly 20,000 people in the US with about 4,000 newly treated each year and no combination option on the market. Karyopharm pegs the peak US revenue opportunity at up to $1 billion and plans to lean on the commercial infrastructure it already runs for XPOVIO, including its KaryForward patient support program, to move quickly if approved. On the existing business, XPOVIO generated $30.8 million in U.S. net product revenue in the quarter, with demand holding roughly flat from a year earlier even as the treatment landscape gets more crowded.
Bear Case: A Runway That Ends In Weeks
The financial picture is where the caution belongs. Total revenue fell to $33.4 million from $37.9 million a year earlier, largely because Menarini’s reimbursement of development costs ended in late 2025, a roughly $6.5 million swing. Net loss widened to $67 million from $37.3 million, and while some of that reflects non-cash mark-to-market adjustments tied to the company’s financing structure, the cash balance tells its own story: $65.4 million in cash, equivalents, and investments at quarter end. Management said that funds current plans only through September 2026. A $15.8 million term loan payment is due September 10, and if it goes out without additional financing or a lender waiver, cash would fall below the $10 million minimum liquidity covenant, an event of default.
Compounding the pressure, Karyopharm’s Phase III trial in endometrial cancer missed statistical significance on its primary endpoint despite a numerical improvement in progression-free survival, pushing the company to scale back that program and narrow its focus to myelofibrosis and multiple myeloma. Third quarter expenses are also expected to run modestly above the second quarter as the company manages this transition. Karyopharm says it is actively evaluating financing and strategic alternatives, but nothing has closed yet.
Traders Are Already Circling
Hedge fund ownership rose to 24 funds from 21 the prior quarter, a modest uptick in institutional interest heading into a binge of catalysts. Short interest, meanwhile, sits at 33.51% of the float, a level that signals heavy skepticism and a crowded bearish trade. That combination points to a market that sees both the clinical upside and the balance sheet risk clearly.
Conclusion
Karyopharm has built a legitimate scientific and commercial case for selinexor in myelofibrosis, backed by Phase III data the FDA has already engaged with constructively. But that case now runs on a financing clock measured in weeks, not quarters. For the bulls, the sNDA submission and a resolved balance sheet would remove the biggest overhang at once.
While we acknowledge the risk and potential of KPTI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than KPTI and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center